β-adrenergic receptor antagonists and fracture risk: A meta-analysis of selectivity, gender, and site-specific effects

Osteoporosis International

Volumn 25, Issue 1, 2014, Pages 121-129

  Toulis, K A ^a   Hemming, K ^b   Stergianos, S ^c   Nirantharakumar, K ^b,d   Bilezikian, J P ^e  

^a 424 General Army Hospital   (Greece)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c SUNDSVALL HOSPITAL   (Sweden)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e Columbia University ^*  (United States)

Author keywords

adrenergic antagonists; Fracture; Osteoporosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EFFECT SIZE; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; SPINE FRACTURE; VERY ELDERLY; WRIST FRACTURE;

ADRENERGIC BETA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOREARM INJURIES; HIP FRACTURES; HUMANS; MALE; OSTEOPOROTIC FRACTURES; RISK FACTORS; SEX FACTORS; SPINAL FRACTURES;

EID: 84891840082     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2498-z     Document Type: Article

References (49)

1. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197-207 (Pubitemid 30064908)
2. Ma Y, Nyman JS, Tao H, Moss HH, Yang X, Elefteriou F (2011) Beta2-adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone. Endocrinology 152:1412-1422
3. Takeda S, Karsenty G (2008) Molecular bases of the sympathetic regulation of bone mass. Bone 42:837-840
4. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317 (Pubitemid 35345151)
5. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514-520 (Pubitemid 40477060)
6. Patel MS, Elefteriou F (2007) The new field of neuroskeletal biology. Calcif Tissue Int 80:337-347 (Pubitemid 46897447)
7. Elefteriou F (2005) Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 62:2339-2349 (Pubitemid 41500549)
8. Elefteriou F (2008) Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 473:231-236
9. Toulis KA, Anastasilakis AD, Polyzos SA, Makras P (2011) Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Horm (Athens) 10:174-195
10. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25:1341-1362 (Pubitemid 39004105)
11. Wiens M, Etminan M, Gill SS, Takkouche B (2006) Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 260:350-362 (Pubitemid 44370908)
12. Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581-589 (Pubitemid 43261923)
13. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV (2011) Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 48:451-455
14. Meisinger C, Heier M, Lang O, Doring A (2007) Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 18:1189-1195 (Pubitemid 47300270)
15. Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL (2007) Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 40:1209-1216 (Pubitemid 46553796)
16. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 80:69-75 (Pubitemid 46294972)
17. Solomon DH, Mogun H, Garneau K, Fischer MA (2011) Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 26:1561-1567
18. Sosa M, Saavedra P, Gomez de Tejada MJ, Mosquera J, Perez-Cano R, Olmos JM, Munoz-Torres M, Amerigo MJ, Moro MJ, Diaz-Curiel M, Alegre J, Malouf J, Del Pino J, Nogues X, Torrijos A (2011) Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin Exp Res 23:112-117
19. Song HJ, Lee J, Kim YJ, Jung SY, Kim HJ, Choi NK, Park BJ 2012 beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients. Bone
20. Turker S, Karatosun V, Gunal I (2006) Beta-blockers increase bone mineral density. Clin Orthop Relat Res 443:73-74 (Pubitemid 44324936)
21. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 166:241-246 (Pubitemid 43144951)
22. Reid IR (2008) Effects of beta-blockers on fracture risk. J Musculoskelet Neuronal Interact 8:105-110
23. Ilic K, Obradovic N, Vujasinovic-Stupar N (2013) The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 92:217-227
24. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292:1326-1332 (Pubitemid 39223223)
25. Peacock M, Buckwalter KA, Persohn S, Hangartner TN, Econs MJ, Hui S (2009) Race and sex differences in bone mineral density and geometry at the femur. Bone 45:218-225
26. Riggs BL, Melton III LJ III, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S (2004) Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 19:1945-1954 (Pubitemid 41103408)
27. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, Peterson JM, Melton LJ III (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21:124-131 (Pubitemid 43023234)
28. Peacock M, Koller DL, Lai D, Hui S, Foroud T, Econs MJ (2009) Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait loci. Bone 45:443-448
29. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301-1309
30. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ (2005) Indirect comparisons of competing interventions. Health Technol Assess 9:1-134, III-iv
31. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 19:19-24 (Pubitemid 41295133)
32. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC (2005) beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613-618 (Pubitemid 40393069)
33. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365-372 (Pubitemid 40100883)
34. Levasseur R, Dargent-Molina P, Sabatier JP, Marcelli C, Breart G (2005) Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J Am Geriatr Soc 53:550-552 (Pubitemid 41623546)
35. Jensen J, Nielsen LH, Lyhne N, Hallas J, Brosen K, Gram LF (1991) Drugs and femoral neck fracture: a case-control study. J Intern Med 229:29-33
36. van Staa TP, Dennison EM, Leufkens HG, Cooper C (2001) Epidemiology of fractures in England and Wales. Bone 29:517-522 (Pubitemid 33124293)
37. Bazelier M, de Boer A, de Vries F (2012) Acid suppressants and hip fracture: duplicate publication bias? Bone 49:920, author reply 921
38. Aitken SJ, Landao-Bassonga E, Ralston SH, Idris AI (2009) Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Arch Biochem Biophys 482:96-103
39. Kondo H, Togari A (2011) Continuous treatment with a low-dose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88:23-32
40. Nagao M, Feinstein TN, Ezura Y, Hayata T, Notomi T, Saita Y, Hanyu R, Hemmi H, Izu Y, Takeda S, Wang K, Rittling S, Nakamoto T, Kaneko K, Kurosawa H, Karsenty G, Denhardt DT, Vilardaga JP, Noda M (2011) Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A 108:17767-17772
41. Hanyu R, Wehbi VL, Hayata T, Moriya S, Feinstein TN, Ezura Y, Nagao M, Saita Y, Hemmi H, Notomi T, Nakamoto T, Schipani E, Takeda S, Kaneko K, Kurosawa H, Karsenty G, Kronenberg HM, Vilardaga JP, Noda M (2012) Anabolic action of parathyroid hormone regulated by the beta2-adrenergic receptor. Proc Natl Acad Sci U S A 109:7433-7438
42. Rodrigues WF, Madeira MF, da Silva TA, Clemente-Napimoga JT, Miguel CB, Dias-da-Silva VJ, Barbosa-Neto O, Lopes AH, Napimoga MH (2012) Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. Br J Pharmacol 165:2140-2151
43. Bonnet N, Benhamou CL, Malaval L, Goncalves C, Vico L, Eder V, Pichon C, Courteix D (2008) Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol 217:819-827
44. Pierroz DD, Bonnet N, Bianchi EN, Bouxsein ML, Baldock PA, Rizzoli R, Ferrari SL (2012) Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J Bone Miner Res 27:1252-1262
45. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16:612-619 (Pubitemid 47039527)
46. Schmitt CP, Obry J, Feneberg R, Veldhuis JD, Mehls O, Ritz E, Schaefer F (2003) Beta1-adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol 14:3245-3250 (Pubitemid 37509300)
47. Majumdar SR, Ezekowitz JA, Lix LM, Leslie WD (2012) Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab 97:1179-1186
48. Cruickshank JM (1980) The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100:160-178 (Pubitemid 10056025)
49. Yang S, Nguyen ND, Eisman JA, Nguyen TV (2012) Association between beta-blockers and fracture risk: a Bayesian meta-analysis. Bone 51:969-974